From sensing outbreaks to breakthrough cures, do more with AI

The pharmaceuticals and life sciences sector is in the throes of change. The rise of specialty drugs catering to smaller patient populations has complicated both clinical trials and regulatory approvals. As already long research and development timelines extend further, it will stretch the capacity of pharmaceuticals companies to launch new drugs. Amidst tough conditions, the search for efficiency, agility and efficacy in bringing products to market is assuming greater urgency. That quest is driving adoption of Artificial Intelligence (AI) and automation in the industry. The decision to deploy AI is driven equally by the need to acquire competitive advantage and a push from the executive leadership. But there are ethical issues to tackle as well. Download our exclusive report to find out how the pharmaceuticals and life sciences industry is getting ready for the AI advantage.


Bringing smart automation to the life sciences industry

The spiraling costs of care, aging populations, and the emergence of epidemic conditions have rendered the care models of yesterday inadequate. The opportunity of our times is to bring automation to not only better these existing models, but also to create new ones entirely.

In these digital times when patients expect differentiated experiences, pharmaceuticals and life sciences industry must leverage technology-led innovations. These include wearable sensors, social analytics and a host of new apps that deliver predictive diagnostics and preventive care while co-opting patients into the process of health management. Infosys helps its life sciences customers harness the power of Design Thinking principles, automation and deep industry knowledge to improve research analytics, digitize clinical trials, and ensure regulatory compliance while improving patient safety. Explore our platforms and solutions to find out how you can innovate and Be More for consumers counting on your care.